Michael Heuer - Roche Holding CEO
RHHVF Stock | USD 256.16 3.76 1.49% |
CEO
Dr. Michael Heuer is no longer a Member of the Corporationrationrate Executive Committee, Interim Chief Executive Officer Roche Diagnostics at Roche Holding Ltd effective July 31st, 2019. He Heuer joined Boehringer Mannheim in 1983 and was appointed to his current position in 2018. Following the acquisition of Boehringer Mannheim by Roche in 1998, he held various management positions in sales, marketing and product development in Germany, Austria and the United States before being appointed Head of Roche Near Patient Testing business unit. Prior to his current role, he was Head of Diagnostics Europe, Middle East, Africa and Latin America region. Michael Heuer holds a PhD in Chemistry from the University of Kiel. since 2018.
Age | 64 |
Tenure | 6 years |
Professional Marks | Ph.D |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 14 records | CEO Age | ||
Elizabeth Barrett | Novartis AG ADR | 56 | |
Michael Ball | Novartis AG ADR | 62 | |
Osamu Nagayama | Roche Holding | 69 | |
Bruno Strigini | Novartis AG ADR | N/A | |
William Anderson | Roche Holding | 57 | |
Severin Schwan | Roche Holding | 56 | |
Paul Hudson | Novartis AG ADR | 51 | |
Chris Ilsley | Novartis AG ADR | N/A | |
Francesco Balestrieri | Novartis AG ADR | N/A | |
PerOlof Attinger | Roche Holding | 58 | |
Richard Saynor | Novartis AG ADR | 57 | |
Jacob Naarden | Eli Lilly And | 39 | |
Pascal Soriot | AstraZeneca PLC ADR | 60 | |
Joseph Jimenez | Novartis AG ADR | 58 |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
Bruno Eschli, Head Relations | ||
Silvia Ayyoubi, Head of Group HR | ||
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
Thomas Schinecker, Chief Diagnostics | ||
Beatrice Mauro, Non-Executive Director | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
Gottlieb Keller, General Counsel and Corporate Secretary | ||
Urs Jaisli, Chief Compliance Officer | ||
Daniel ODay, COO of Pharmaceuticals division | ||
Claudia Bockstiegel, G Counsel | ||
DeAnne Julius, Non-Executive Director | ||
Johannes MD, Head Devel | ||
Karl Mahler, Head of Investor Relations | ||
Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
Claudia Dyckerhoff, Non-Executive Director | ||
Fritz Gerber, Honorary Chairman of the Board | ||
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
Julie Brown, Non-Executive Director | ||
Richard Lifton, Non-Executive Director | ||
Paul Bulcke, Non-Executive Director | ||
Christoph Franz, Non-Executive Director | ||
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
Pascale Schmidt, Chief Officer | ||
Pius Baschera, Non-Executive Director | ||
Peter Voser, Non-Executive Director | ||
Bernard Poussot, Non-Executive Director | ||
John Bell, Non-Executive Director | ||
Andreas Oeri, Non-Executive Director | ||
Alan Hippe, CFO and IT Officer | ||
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
F Hoffmann, IR Contact Officer | ||
Severin Schwan, CEO and Director | ||
Anita Hauser, Non-Executive Director | ||
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 287.91 B | |||
Shares Outstanding | 693.89 M | |||
Shares Owned By Institutions | 40.30 % | |||
Price To Earning | 18.04 X | |||
Price To Book | 9.57 X | |||
Price To Sales | 3.97 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |